Fox Run Management L.L.C. Invests $282,000 in Harrow, Inc. $HROW

Key Points

• Fox Run Management L.L.C. purchased 10,604 shares of Harrow, Inc., valued at approximately $282,000, marking a new stake according to its latest SEC filing.
• Analysts have shown bullish sentiment towards Harrow, with a range of price targets setting the stock's average at $64.67 and most analysts rating it as a "Buy" or "Strong Buy."
• Harrow's most recent earnings report revealed a significant EPS of $0.24, outperforming the expected $0.01, with quarterly revenue of $63.74 million.

Fox Run Management L.L.C. purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,604 shares of the company's stock, valued at approximately $282,000.

Other institutional investors have also modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Harrow by 89.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock worth $2,078,000 after acquiring an additional 29,262 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after acquiring an additional 6,027 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Harrow by 7.5% during the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after acquiring an additional 22,266 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Harrow by 8.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company's stock worth $640,000 after acquiring an additional 1,428 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Trading Up 2.5%

HROW traded up $0.96 during trading on Friday, hitting $39.12. The company's stock had a trading volume of 618,433 shares, compared to its average volume of 659,886. The firm's 50 day moving average price is $33.93 and its 200-day moving average price is $29.16. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The stock has a market cap of $1.45 billion, a PE ratio of -156.48 and a beta of 0.41. Harrow, Inc. has a twelve month low of $20.85 and a twelve month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.23. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. On average, analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 price target on the stock. HC Wainwright upped their target price on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. William Blair started coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating on the stock. BTIG Research upped their target price on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Finally, Zacks Research raised Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to MarketBeat.com, Harrow currently has a consensus rating of "Buy" and an average target price of $64.67.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.